Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.

Weight-inclusive health care is the provision of equitable care without perpetuating weight stigma among patients of all body ...

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications for weight loss are significantly transforming the fiel ...

Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance ...

UK: A recent consensus statement from leading UK medical organizations-including the Association of Anaesthetists,the ...

Boone Health is closing its bariatric clinic in Columbia because of lagging demand. "We're working to expand the high-demand ...

Among patients with type 2 diabetes, use of GLP-1 agonists may increase the risks for adhesive capsulitis and required ...

As the body of research expands on the potential of glucagon-like peptide-1 receptor agonists to address various health ...

As demand remains high for GLP-1 drugs, primary care physicians are concerned about the risks of patients using third-party ...

A new and surprising side effect from GLP-1 weight loss drugs is boosting business for plastic surgeons.Facial plastic ...

Surgical tweaks for “Ozempic face” are on the rise. The latest report from AAFPRS reveals a 50% increase in facial fat ...